References
- Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995;9:43–9
- Perry RJ, Hodges JR. Fate of patients with questionable (very mild) Alzheimer’s disease: longitudinal profiles of individual subjects’ decline. Dement Geriatr Cogn Disord 2000;11:342–9
- Muramoto O, Sugishita M, Sugita H, Toyokura Y. Effect of physostigmine on constructional and memory tasks in Alzheimer’s disease. Arch Neurol 1979;36:501–3
- Sahakian BJ, Coull JT. Tetrahydroaminoacridine (THA) in Alzheimer’s disease: an assessment of attentional and mnemonic function using CANTAB. Acta Neurol Scand 1993;149:29–35
- Howe MN, Price IR. Effects of transdermal nicotine on learning, memory, verbal fluency, concentration, and general health in a healthy sample at risk for dementia. Int Psychogeriatr 2001;13: 465–75
- Bourin M, Ripoll N, Dailly E. Nicotinic receptors and Alzheimer’s disease. Curr Med Res Opin 2003;19:169–77
- Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 2001;49:279–88
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76
- Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261–8
- Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Br Med J 2000;321:1445–9
- Wesnes KA, Scott M, Morrison S, Greenwood D, Russell-Duff K, Wilcock GK. The effects of galantamine on attention in Alzheimer’s disease. Psychopharmacology 1998;12:A46
- Foldi NS, Lobosco JL, Schaefer LA. The effect of attentional dysfunction in Alzheimer’s disease: theoretical and practical implications. Semin Speech Lang 2002;23:139–50
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
- Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
- Wesnes KA, Scott M, Boyle M, Surmon DJ, Wilcock GK. Use of the Cognitive Drug Research computerised assessment system to measure the efficacy of THA and galantamine in Alzheimer’s disease. Psychopharmacology Bull 1994;30:139
- Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95–102
- Fakouhi TD, Jhee SS, Sramek JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer’s disease. J Geriatr Psychiatry Neurol 1995;8:226–30
- McKeith I, Del Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised double-blind, placebo-controlled international study. Lancet 2000;356:2031–6
- Newhouse PA, Potter A, Singh A. Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 2004;4:36–46
- Grottick AJ, Haman M, Wyler R, Higgins GA. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 2003;28:880–7
- Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dementia Geriatr Cogn Disord 2002;13:183–92
- Wesnes K, Pincock C. Practice effects on cognitive tasks: a major problem? Lancet Neurology 2002;1:473
- Wesnes K. The Cognitive Drug Research computerised assessment system: application to clinical trials. In: De Deyn P, Thiery E, D’Hooge R, editors. Memory: basic concepts, disorders and treatment. Leuven: Uitgeverij Acco; 2003. p. 453–72
- Ballard C, O’Brien J, Gray A, et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001;58:977–82
- Vitaliano PP, Breen AR, Albert MS, Russo J, Prinz PN. Memory, attention, and functional status in community-residing Alzheimer type dementia patients and optimally healthy aged individuals. J Gerontol 1984;39:58–64
- Duchek JM, Hunt L, Ball K, Buckles V, Morris JC. The role of selective attention in driving and dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1997;11:48–56